NCT02862275View on ClinicalTrials.gov

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

November 21, 2026

Study Completion Date

November 21, 2026

Conditions
Hematopoietic and Lymphoid Cell NeoplasmMetastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
Interventions
DRUG

Atezolizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood specimen collection

PROCEDURE

Computed Tomography

Undergo CT scan

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (9)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

77030

M D Anderson Cancer Center, Houston

92093

UC San Diego Moores Cancer Center, La Jolla

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH